Our team has experience spanning the globe, including the Americas, Asia, Europe, India, South Africa, and Australia, bringing a strong global perspective to the clinical development, Medical Sciences, Biometrics, and Medical Writing services we offer. InClin has an established network of highly experienced project managers and field monitors throughout the United States, Europe, and Asia, in addition to world-class Biometrics and Medical Writing support. This extremely flexible team is committed to providing close personal attention and support to each project and is the driving force behind our success.
Arnold G. Wong (Cofounder and Chief Executive Officer) has hands-on experience in pre-clinical research and extensive experience in clinical research. Before becoming CEO of InClin, Mr. Wong was the CFO of InClin since its’ inception in 1998. He held positions of an Associate Scientist at Cardima, Inc., COR Therapeutics, and Syntex Research. Previously, as InClin Senior Project Manager, Mr. Wong was responsible for management of clinical operations teams and liaison with Sponsor clients. Mr. Wong has a BS in physiology from the University of California at Davis.
Taylor T. Kilfoil (Cofounder and Chief International Officer) was the previous President and Chief Executive Officer of InClin. Mr. Kilfoil has 25+ years of pharmaceutical and biotech industry experience. Since cofounding InClin in 1998, Mr. Kilfoil has held a wide spectrum of senior level consultant positions at multiple pharmaceutical and biotechnology companies where he provided both clinical operations and project management support for their domestic and international clinical development programs. He started his career at Syntex Research conducting nonclinical pharmacology drug development research where he moved into the clinical research arena. Mr. Kilfoil has extensive experience in Phase 1 to 3 drug development. Mr. Kilfoil has a BS in psychobiology from Saint John’s University.
Brian Horger, PhD
Brian Horger, Ph.D (Vice President, Business Development and Chief Operations Officer) has broad and extensive experience in the pharmaceutical and drug development industry. Dr. Horger began his career as a Research Scientist at Yale University School of Medicine. Subsequently he held industry positions and led drug discovery efforts in Parkinson’s Disease at Genentech and smooth muscle disorders at Theravance. Over the last 10 years Dr. Horger has served as a Director of Business Development at MDS Pharma Services and Covance Early Clinical Services. Dr. Horger has a PhD in Neuroscience from Texas A&M University.
Frederick Hausheer, MD, PhD, FACP
Frederick Hausheer (Chief Medical Officer and Sr. Vice President of Medical Science) is a recognized expert in drug discovery, pharmacology, clinical drug development, pharmaceutical application software, as well as supercomputing development. Dr. Hausheer has been in practice for more than two decades and his areas of expertise remain global research, drug development, and oncology. Dr. Hausheer is board certified in Internal Medicine and Medical Oncology and has been a National Cancer Institute designated clinical investigator since 1985. He is a fellow of the American College of Physicians and was a senior scientist at the Advanced Scientific Computing Laboratory at the National Cancer Institute. Dr. Hausheer completed his training in Medical Oncology at The Johns Hopkins Oncology Center with training in experimental therapeutics and the pharmacology of investigational drugs. He continues to hold an adjunct professorship at Johns Hopkins. Dr. Hausheer received an M.D. degree (with honors) from the University of Missouri.
George F. Faurot (Senior Vice President, Clinical Operations) has hands-on preclinical research experience (7 years) and extensive experience in clinical research (17 years). Previously, as Senior Partner and Vice President, Clinical Operations at InClin, Mr. Faurot was responsible for the planning, implementation, and execution of Phase 1 to 3 clinical development programs for multiple pharmaceutical sponsors, 3 of which resulted in successful NDA approvals. Mr. Faurot has a BS in environmental toxicology from the University of California at Davis.
Marc R. Perry (Senior Vice President, Quality) is a member of the original management team that founded InClin and has served as a managing partner contributing to the successful growth of the company during the past 14 years. Mr. Perry has hands-on nonclinical research experience and broad global clinical operations experience derived from Global Project Management positions responsible for managing multiple global Phase 3 programs. The development programs Mr. Perry has helped manage have led to 2 successful NDA submissions and 2 market approvals. Mr. Perry studied biological sciences at the University of Montana and pharmacology at the University of California, Santa Barbara.
Mojtaba Noursalehi, PhD
Mojtaba “Mo” Noursalehi (Senior Vice President, Biometrics) has served as Executive Director of Biometrics for Cytochroma, Astex, Exelixis, and Synteract and been responsible for managing the statistical analysis, programming, and data management activities of all phases of drug development in Oncology, Endocrinology, Transplant, and CNS. Dr. Noursalehi previously held the positions of Senior Director of Biometrics at GPC Biotech, Scirex, Clinsys, Abbott, Tercica, Target Research Associates, and Novartis. Dr. Noursalehi has also held positions of Senior Researcher at the US National Cancer Institute as well as Assistant Professor at Baker University. Dr. Noursalehi received his MSc at the University of California at Los Angeles, his PhD at the University of Kansas, and post doctorate PK/PD training from Stanford University and the University of Maryland. In his 20+ years of clinical research and pharmaceutical industry experience, he has assisted with submitting more than 20 NDAs and BLAs in various therapeutic areas.